Disseny d'un sistema d'indicadors en camins i diagnosi socioambiental del Camí de Cavalls de Menorca 2008 : sector nord-est

Menorca va ser declarada Reserva de la Biosfera per la UNESCO l'any 1993. Entre d'altres, un dels aspectes més emblemàtics de l'Illa és el Camí de Cavalls. Preservar la diversitat que aquest ofereix comporta una gestió complexa. Per això, és necessària per una millor gestió ambiental la realitzacióNota: Aquest document conté originàriament altre material i/o programari només consultable a la Biblioteca de Ciència i Tecnologia.Nota: Aquest projecte està relacionat amb el titulat "Disseny d'un sistema d'indicadors ambientals en camins i diagnosi socioambiental del Camí de Cavalls: sector sud-oest", redactat per Laura Millet, Ma. Elena Miró, Anna Òdena i Anna Olle

Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study)

Carga económica; Fibrosis pulmonar idiopática; EspañaCàrrega econòmica; Fibrosi pulmonar idiopàtica; EspanyaEconomic burden; Idiopathic pulmonary fibrosis; SpainBackground Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease associated with dyspnoea, cough and impaired quality of life affecting around 7500 patients in Spain. Objective Our aim was to estimate the economic impact of IPF according to forced vital capacity (FVC) % predicted level in adult patients. Methods We conducted a prospective, observational, multicentric study of patients with confirmed IPF in Spain. Total annual IPF-related costs were estimated per patient, and categorised according to the FVC% predicted value (FVC 80%) and total sample. Incurred direct health- and non-health-related costs and indirect costs were calculated considering the IPF-related healthcare resource use and the corresponding unitarian costs. Results were updated to 2023 euros. Results Two hundred and four consecutive patients with IPF were included: 77% male, average age (standard deviation) 70.8 (7.6) years. At baseline, FVC% was 80% of predicted value in 10.8%, 74.5% and 14.7% of patients, respectively. The final cost-evaluable population included 180 subjects. The mean (standard deviation) total annual IPF-related cost was €26,997 (17,555), with statistically significant differences (p = 0.0002) between groups: €44,412 (33,389) for the FVC 80%. Annual direct health costs had the greatest weight and included pharmacological treatments [€22,324 (13,773)] and hospitalisation days [€1659 (7362)]. 14 patients had ≥ 1 acute exacerbation of IPF during the study; mean total cost of an acute exacerbation of IPF was €10,372. According to the multivariate analysis, an impaired lung function (FVC < 50%) and use of antifibrotic treatment were determinants of cost (p < 0.0001 both). Conclusions We observed a significantly higher annual IPF-related cost at a lower level of predicted FVC%, the direct cost having the greatest weight to the total costs. Maintaining patients at early disease stages by slowing IPF progression is relevant to reduce the economic impact of IPF

Decreased quality of live and treatment satisfaction in patients with latent autoinmune diabetes of the adult

Objectives. Our main aim was to assess the quality of life (QoL) and treatment satisfaction (TS) of subjects with LADA (latent autoimmune diabetes of the adult) and compare these measures with those of patients with other diabetes types, i.e., type 1 (T1DM) and type 2 diabetes mellitus (T2DM). Methods. This was a cross-sectional study with a total of 48 patients with LADA, 297 patients with T2DM and 124 with T1DM. The Audit of Diabetes-Dependent Quality of Life (ADDQoL-19) questionnaire and the Diabetes Treatment Satisfaction Questionnaire (DTSQ) were administered. Relevant clinical variables were also assessed. The data analysis included comparisons between groups and multivariate linear models. Results. The LADA patients presented lower diabetes-specific QoL (p D 0:045) and average weighted impact scores (p D 0:007) than the T2DM patients. The subgroup of LADA patients with diabetic retinopathy (DR) who were treated with insulin had a lowerADDQoLaverage weighted impact score than the other diabetic groups. Although the overall measure of TS was not different between the LADA and T2DM (pD0:389) and T1DM (pD0:091) groups, the patients with LADA showed a poorer hyperglycemic frequency perception than the T2DM patients (p<0:001) and an improved frequency of hypoglycemic perception compared with the T1DM patients (pD0:021). Conclusions. The current findings suggest a poorer quality of life, especially in terms of DRand insulin treatment, among patients with LADA compared with those withT1DM and T2DM. Hyperglycemia frequency perception was also poorer in the LADA patients than in the T1DM and T2DM patients. Further research with prospective studies and a large number of patients is necessary.This study was supported by grant PS09/01035 and PI12/00183 from the Instituto de Salud Carlos III, Ministry of Economy and Competitiveness, Spain. CIBERDEM is an initiative from Instituto de Salud Carlos III (Plan Nacional de I+D+I and Fondo Europeo de Desarrollo Regional). MGC holds a predoctoral fellowship from the Ministerio de Educación, Cultura y Deporte (FPU15/03005)

Role of the Scavenger Receptor CD36 in Accelerated Diabetic Atherosclerosis

Diabetes mellitus entails increased atherosclerotic burden and medial arterial calcification, but the precise mechanisms are not fully elucidated. We aimed to investigate the implication of CD36 in inflammation and calcification processes orchestrated by vascular smooth muscle cells (VSMCs) under hyperglycemic and atherogenic conditions. We examined the expression of CD36, pro-inflammatory cytokines, endoplasmic reticulum (ER) stress markers, and mineralization-regulating enzymes by RT-PCR in human VSMCs, cultured in a medium containing normal (5 mM) or high glucose (22 mM) for 72 h with or without oxidized low-density lipoprotein (oxLDL) (24 h). The uptake of 1,1'-dioctadecyl-3,3,3',3-tetramethylindocarbocyanine perchlorate-fluorescently (DiI) labeled oxLDL was quantified by flow cytometry and fluorimetry and calcification assays were performed in VSMC cultured in osteogenic medium and stained by alizarin red. We observed induction in the expression of CD36, cytokines, calcification markers, and ER stress markers under high glucose that was exacerbated by oxLDL. These results were confirmed in carotid plaques from subjects with diabetes versus non-diabetic subjects. Accordingly, the uptake of DiI-labeled oxLDL was increased after exposure to high glucose. The silencing of CD36 reduced the induction of CD36 and the expression of calcification enzymes and mineralization of VSMC. Our results indicate that CD36 signaling is partially involved in hyperglycemia and oxLDL-induced vascular calcification in diabetes

Poorer Quality of Life and Treatment Satisfaction is Associated with Diabetic Retinopathy in Patients with Type 1 Diabetes without Other Advanced Late Complications

Diabetic retinopathy (DR) may potentially cause vision loss and affect the patient's quality of life (QoL) and treatment satisfaction (TS). Using specific tools, we aimed to assess the impact of DR and clinical factors on the QoL and TS in patients with type 1 diabetes. This was a cross-sectional, two-centre study. A sample of 102 patients with DR and 140 non-DR patients were compared. The Audit of Diabetes-Dependent Quality of Life (ADDQoL-19) and Diabetes Treatment Satisfaction Questionnaire (DTSQ-s) were administered. Data analysis included bivariate and multivariable analysis. Patients with DR showed a poorer perception of present QoL (p = 0.039), work life (p = 0.037), dependence (p = 0.010), and had a lower average weighted impact (AWI) score (p = 0.045). The multivariable analysis showed that DR was associated with a lower present QoL (p = 0.040), work life (p = 0.036) and dependence (p = 0.016). With regards to TS, DR was associated with a higher perceived frequency of hypoglycaemia (p = 0.019). In patients with type 1 diabetes, the presence of DR is associated with a poorer perception of their QoL. With regard to TS, these subjects also show a higher perceived frequency of hypoglycaemia.This study was supported by the Catalan Diabetes Association (Beca d’Educació Terapèutica 2015), Spain. Additional support from grants PI12/00183 and PI15/00625 from the Instituto de Salud Carlos III (Ministry of Economy and Competitiveness, Spain) to DM is acknowledged. CIBERDEM is an initiative from the Instituto de Salud Carlos III (Plan Nacional de I + D + I and Fondo Europeo de Desarrollo Regional). M.G.-C. holds a predoctoral fellowship from the Ministerio de Educación, Cultura y Deporte, FPU15/03005

Calcium phosphate product is associated with subclinical carotid atherosclerosis in type 2 diabetes

Aims. To assess whether circulating 25-hydroxyvitamin D3 (25OHD) and mineral metabolism-related factors (serum phosphate, calcium, and parathormone) are associated with subclinical carotid atherosclerosis (SCA), defined as the presence of carotid atherosclerotic plaques (main study outcome), in patients with type 2 diabetes mellitus (T2DM) without kidney disease or previous cardiovascular disease. Methods. We undertook a post hoc analysis of a cross-sectional study in adults with T2DM in whom we evaluated SCA. A total of 303 subjects with T2DM were included. Clinical variables and carotid ultrasound imaging were obtained. Results. We found no association of 25OHD with the presence of SCA. However, calcium phosphate (CaP; mg2/dL2) product was positively associated with the presence of carotid plaques (ORadj = 1.078; 95% CI: 1.017–1.142). An inverse association was observed between higher levels of 25OHD (≥30 ng/mL versus <20 ng/mL concentrations) and common carotid intima-media thickness (cIMT; mm) (βadj ± SE = −0.055 ± 0.024). We conclude that the CaP product is independently associated with the presence of established subclinical carotid atherosclerosis in patients with T2DM.This study was supported by Grants PS09/01035 and PI15/ 00625 from Instituto de Salud Carlos III, Ministry of Economy and Competitiveness, Spain. CIBERDEM is an initiative from Instituto de Salud Carlos III (Plan Nacional de I+D+I and Fondo Europeo de Desarrollo Regional). Minerva Granado-Casas holds a predoctoral fellowship from Ministerio de Educación, Cultura y Deporte, FPU15/03005

Actualitzacions en terapèutica farmacològica: avenços 2015; novetats que canvien la pràctica clínica

Terapèutica farmacològica; Avenços; Pràctica clínicaTerapeutica farmacológica; Avances; Práctica clínicaPharmacological therapy; Advances; Clinical practiceEste informe identifica las cuestiones relacionadas con la terapéutica farmacológica consideradas mas relevantes para la práctica clínica, considerando aspectos muy diversos como son las nuevas estrategias terapéuticas, prácticas relacionadas con la sobreutilización de medicamentos, cuestiones sobre la continuidad, el avance y la suspensión de los tratamientos, los nuevos medicamentos y los pros y contras de alternativas terapéuticas que se han ido planteando específicamente a lo largo del año 2014.Aquest informe identifica les qüestions relacionades amb la terapèutica farmacològica considerades més rellevants per a la pràctica clínica, considerant aspectes ben diversos com ara les noves estratègies terapèutiques, pràctiques relacionades amb la sobreutilització de medicaments, qüestions sobre la continuïtat, l‟avançament i la suspensió dels tractaments, els nous medicaments, i els pros i contres d‟alternatives terapèutiques que s‟han anant plantejat específicament al llarg de l'any 201

Temporada de pesca

Treballs de l'alumnat del Grau de Comunicació Audiovisual, Facultat d'Informació i Mitjans Audiovisuals, Universitat de Barcelona, Projectes II. Curs: 2019-2020, Tutor: Francesc Llinares. // Director: Guillem Villalonga i Colomé; Aj. Direcció: Ivette Herrero Serrano i Claudia Turmo Margalef; Direcció dárt: Ivette Herrero Serrano; Productor: Bernat Morros González; Aj. Producció: Marta Millán Jiménez, Lorena Sanchiz Rodríguez i Aina Cruz Arcas; Script i claqueta: Marta Millán Jiménez, Lorena Sanchiz Rodríguez i Claudia Turmo Margalef; Guionista: Guillem Villalonga i Colomé; Dir. Fotografia: Gabriel Alonso Díez; Càmera: Walter Luis Altamirano Castillo; Aj. càmera: Guillem Villalonga i Colomé; Il·luminador: Gabriel Alonso Díez; Storyboard: Claudia Turmo Margalef; Direcció de so: Bernat Morros González; Muntatge: Walter Luis Altamirano Castillo; Música: Roger Albet; Postproducció: Gabriel Alonso Díez. Equip artístic: Irieix Freixas, Aina Cruz Arcas, Elies Villalonga, Pau Rumbo, Claudia Turmo Margalef, Lorena Sanchiz Rodríguez, Marta Millán Jiménez, Gabriel Alonso Díez, Ivette Herrero Serrano, Mariona Fortuny i Guillem Villalonga i Colomé.Sato, un jove turmentat psicològicament per l’educació del seu pare, segresta turistes que no es comporten com ell creu correcte. Una noia que acaba d’arribar al poble on viu es fixa amb ell i s’enamoren. El canvi que la relació estava generant en tots dos es veu aturat quan ella descobreix els segrestos

Mycobacterium manresensis induces trained immunity in vitro

The COVID-19 pandemic posed a global health crisis, with new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants weakening vaccine-driven protection. Trained immunity could help tackle COVID-19 disease. Our objective was to analyze whether heat-killed Mycobacterium manresensis (hkMm), an environmental mycobacterium, induces trained immunity and confers protection against SARS-CoV-2 infection. To this end, THP-1 cells and primary monocytes were trained with hkMm. The increased secretion of tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-1β, and IL-10, metabolic activity, and changes in epigenetic marks suggested hkMm-induced trained immunity in vitro. Healthcare workers at risk of SARS-CoV-2 infection were enrolled into the MANRECOVID19 clinical trial (NCT04452773) and were administered Nyaditum resae (NR, containing hkMm) or placebo. No significant differences in monocyte inflammatory responses or the incidence of SARS-CoV-2 infection were found between the groups, although NR modified the profile of circulating immune cell populations. Our results show that M. manresensis induces trained immunity in vitro but not in vivo when orally administered as NR daily for 14 days. Biological sciences; Molecular biology; Immunology; Microbiolog